VENLO, Netherlands & HILDEN, Germany – (COMMERCIAL THREAD) – QIAGEN NV (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has been selected for inclusion in the DAX (Deutscher Aktienindex), the leading German stock index in Germany.
“Joining the ranks of the largest German listed companies is an important step and a success for QIAGEN”, said Thierry Bernard, CEO of QIAGEN NV “The relevance of molecular tests to fight diseases, develop drugs and conquer markets scientific frontiers has never been so strong. . Our people are the reason for this achievement and have never been more committed to realizing our vision at QIAGEN of making life better possible. ”
Roland Sackers, Chief Financial Officer of QIAGEN, added: “Our inclusion in the DAX 40 is recognition of the progress QIAGEN has made in generating long-term profitable growth and creating value for shareholders and other stakeholders. Even more important has been the contribution of QIAGEN’s solutions to increasing our knowledge of the biology of life and improving patient outcomes. It goes to the heart of what our employees do every day and has a significant impact on daily life around the world. ”
QIAGEN was built on a revolutionary way to extract DNA – made up of the building blocks of life – from a wide variety of biological samples. As a spin-off of the University of Düsseldorf, QIAGEN has grown into a global company on track to achieve more than $ 2 billion in sales by 2021. With approximately 6,000 employees worldwide, the head office of QIAGEN is in Venlo, the Netherlands, while the operational headquarters site is in Hilden, Germany.
QIAGEN is implementing a successful growth strategy that aims to create significant value for its stakeholders, including its shareholders. The company’s portfolio of Sample to Insight addresses the growing molecular testing needs of customers across the continuum of pharmaceutical research and R&D in life sciences to clinical molecular diagnostics.
Changes to the DAX, which is broadened to include the 40 largest companies by market capitalization, are expected to take place on Monday, September 20, 2021. This is also the date when QIAGEN will no longer be included in the German MDAX, which will now be the index of the next 50 companies based on market capitalization after the DAX.
QIAGEN also remains a member of German TecDAX, which brings together the 30 largest German companies in the technology sector. Additionally, QIAGEN’s global stocks are listed on the New York Stock Exchange (NYSE), making it one of the few companies listed on the stock exchanges in both countries.
For more information, please visit http://www.qiagen.com
QIAGEN NV, a Netherlands-based holding company, is the world’s leading provider of Sample to Insight solutions that enable customers to gain valuable molecular information from samples containing the building blocks of life. Our sampling technologies isolate and process DNA, RNA and proteins from blood, tissues and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to yield relevant and actionable information. Automation solutions connect them in transparent and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers worldwide in the fields of molecular diagnostics (human health) and life sciences (universities, pharmaceutical R&D and industrial applications, mainly forensics). As of June 30, 2021, QIAGEN employed approximately 5,900 people at more than 35 locations around the world. Further information is available at http://www.qiagen.com
Source: QIAGEN SA